Fundraising FoxAPIM Therapeutics
4 known investors
Find your way into APIM Therapeutics
Sign up to find every way you can get introduced to APIM Therapeutics
- Your email: who you already know at APIM Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the APIM Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
APIM Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting peptide therapeutics that disrupt cellular stress responses and address treatment resistance in cancer. Its lead candidate, ATX-101, has been evaluated in Phase Ib and Phase II clinical studies for ovarian cancer and soft tissue sarcoma.
Investors · 4
Also in the syndicate · 2
Ro InvestSarsia Seed
Funding
SEC filings, press & company announcements- Undisclosed amountSeed-Follow-Up Financing RoundNov 2011
Birk Venture, Ro Invest, Sarsia Seed
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does APIM Therapeutics do?
- APIM Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting peptide therapeutics that disrupt cellular stress responses and address treatment resistance in cancer. Its lead candidate, ATX-101, has been evaluated in Phase Ib and Phase II clinical studies for ovarian cancer and soft tissue sarcoma.
- Who are APIM Therapeutics's investors?
- APIM Therapeutics's investors include Birk Venture, Sarsia Management AS.